Effects of Short-Term Risedronate on Bone Resorption and Patient Satisfaction in Postmenopausal Osteoporosis Patients

dc.contributor.authorFernandes, Cesar E.
dc.contributor.authorZerbini, Cristiano
dc.contributor.authorRusso, Luis A.
dc.contributor.authorAlbernaz, Marco A.
dc.contributor.authorEis, Sergi R.
dc.contributor.authorSzejnfeld, Vera L. [UNIFESP]
dc.contributor.authorPompei, Luciano M.
dc.contributor.institutionFac Med ABC
dc.contributor.institutionHosp Heliopolis São Paulo
dc.contributor.institutionCCBR Brasil Ctr Anal & Pesquisas Clin
dc.contributor.institutionHosp Materno Infantil Goiania
dc.contributor.institutionCtr Diagnost & Pesquisa Osteoporose Espirito Sant
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.date.accessioned2016-01-24T13:52:04Z
dc.date.available2016-01-24T13:52:04Z
dc.date.issued2009-01-01
dc.description.abstractThis multicenter. open-label study evaluated the effects of short-term risedronate on bone resorption and patient satisfaction in postmenopausal women with osteoporosis in Brazil. Entry requirements included: osteoporosis of the spine/femoral neck diagnosed by a bone mineral density (BMD) T-score <= -2.5 or radiographic fragility fracture within the last year and no treatment with osteoporosis medication in the preceding 3 mo. Patients were treated with once weekly risedronate of 35 mg for 12 wk. Patients also received 1000 mg calcium carbonate and 400 IU vitamin D. the main outcome was the effect on bone resorption, as assessed by the quantification of serum C-telopeptide of type I collagen (CTX). of the 556 women screened, 480 women received >= 1 dose of study drug (intent-to-treat [ITT] population), and 390 completed treatment (81%). After 12 wk, CTX decreased in 94% of patients (from 0.419 +/- 0.234 to 0.158 +/- 0.171 mu g/L, p < 0.0001). Mean CTX reduction was 60.6%. Patient satisfaction was good/excellent in 91.7% of patients. A total of 156 adverse events (AEs) were reported by 113 (23.5%) patients in the ITT population. Digestive symptoms emerged or worsened in 7.1% and 3.5%. respectively. Five patients (1.0%) experienced serious AEs, not considered to be related to risedronate. in conclusion, risedronate significantly reduced scrum CTX after 12-wk treatment. Almost all patients reported good/excellent satisfaction.en
dc.description.affiliationFac Med ABC, Dept Gynecol & Obstet, São Paulo, Brazil
dc.description.affiliationHosp Heliopolis São Paulo, Dept Rheumatol, São Paulo, Brazil
dc.description.affiliationCCBR Brasil Ctr Anal & Pesquisas Clin, Rio de Janeiro, Brazil
dc.description.affiliationHosp Materno Infantil Goiania, Dept Gynecol, Goiania, Go, Brazil
dc.description.affiliationCtr Diagnost & Pesquisa Osteoporose Espirito Sant, Vitoria, Brazil
dc.description.affiliationUniversidade Federal de São Paulo, Dept Rheumatol, Escola Paulista Med, São Paulo, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Dept Rheumatol, Escola Paulista Med, São Paulo, Brazil
dc.description.sourceWeb of Science
dc.description.sponsorshipAlliance for Better Bone Health (Procter Gamble Pharmaceuticals and Sanofi-Aventis)
dc.format.extent77-83
dc.identifierhttp://dx.doi.org/10.1016/j.jocd.2008.09.001
dc.identifier.citationJournal of Clinical Densitometry. New York: Elsevier B.V., v. 12, n. 1, p. 77-83, 2009.
dc.identifier.doi10.1016/j.jocd.2008.09.001
dc.identifier.issn1094-6950
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/31166
dc.identifier.wosWOS:000263234900013
dc.language.isoeng
dc.publisherElsevier B.V.
dc.relation.ispartofJournal of Clinical Densitometry
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.rights.licensehttp://www.elsevier.com/about/open-access/open-access-policies/article-posting-policy
dc.subjectBone resorptionen
dc.subjectosteoporosisen
dc.subjectpostmenopausalen
dc.subjectrisedronateen
dc.subjectsatisfactionen
dc.titleEffects of Short-Term Risedronate on Bone Resorption and Patient Satisfaction in Postmenopausal Osteoporosis Patientsen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções